Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04955938
Title A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University of Chicago

essential thrombocythemia

myeloproliferative neoplasm

polycythemia vera

chronic myeloid leukemia


myelodysplastic/myeloproliferative neoplasm


Enasidenib + Fedratinib

Fedratinib + Ivosidenib

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Chicago Medical Center Recruiting Chicago Illinois 60637 United States Details
*Shaded cells indicate that there was no data available from for the field